I know I am one of the people who speaks about shorting, often but I agree with what you've written here. It may have some impact but it doesn't explain the 12-18 month disconnect from share price performance and the value creation the business has done in that time period so to blame shorting doesn't make sense and I agree with that.
The thing that does seem odd is the amount of turnover (volume) generated. We're a 1.5b market cap company with reasonable shares on issue (125m~), but a single broker/group has generated 78m shares worth of volume of stock in just the last 12 months? Is that considered normal? if we look at the top 5 net sellers who are all US investment banks they've traded 176m shares between themselves and we only have 125m shares on issue. I know they are trading back and forth but they need a reasonable pool of shares to begin with surely?
Maybe that's the case for everything in the indexes and it's just a constant back and forth of computer based trading and rebalancing activities.
- Forums
- ASX - By Stock
- NEU
- Share Price
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.71%
!
$13.07

Share Price, page-15397
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.07 |
Change
0.220(1.71%) |
Mkt cap ! $1.635B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $5.055M | 385.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 340 | $13.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.07 | 343 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 70 | 13.070 |
6 | 367 | 13.060 |
12 | 4315 | 13.050 |
7 | 1399 | 13.040 |
9 | 1393 | 13.030 |
Price($) | Vol. | No. |
---|---|---|
13.080 | 915 | 8 |
13.090 | 1324 | 16 |
13.100 | 2041 | 15 |
13.110 | 1457 | 8 |
13.120 | 1391 | 4 |
Last trade - 13.43pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online